study showing curcumin neutralizes SARS-CoV2 in vitro
with low subtoxic concentrations. Authors note that the clinical use of curcumin is hindered by poor bioavailability, and recommend using methods to increase bioavailability such as nanoparticles, liposomes, micelles, or adjuvants (e.g., piperine).
Bormann et al., 9/23/2021, peer-reviewed, 18 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.